Yazar "Demir, AM" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Arterial Thrombosis in Patients with Primary Immune Thrombocytopenia: A Nationwide Study
    (GALENOS PUBL HOUSE, 2025) Demirci, U; Ümit, EG; Dumludağ, B; Cömert, M; Çiftçiler, R; Özmen, D; Ar, MC; Güven, S; Soyer, Ö; Güney, T; Karabulut, ZT; Yıldız, A; Yaman, S; Aykaş, F; Karakuş, V; İpek, Y; Yılmaz, G; Sadri, S; Baysal, M; Uğur, MC; Pınar, İE; Demir, AM
    Objective: Primary immune thrombocytopenia (pITP) is an acquired bleeding disorder involving decreased numbers of platelets due to platelet destruction or impaired production. The clinical presentation of pITP can be multifaceted and thrombotic events may rarely manifest. Thrombosis can develop with treatment or during the untreated period. The primary objective of this study was to examine the frequency of arterial thromboembolic events (ATEs) in patients with pITP. We also aimed to evaluate the risk factors in these patients and the effect of ITP treatments on ATEs. Materials and Methods: The study was designed as a retrospective multicenter study conducted under the guidance of the Turkish Society of Hematology's Scientific Subcommittee on Hemostasis-Thrombosis. Patients over the age of 18 with pITP who subsequently developed ATE while undergoing follow-up for pITP were evaluated. Results: A total of 2,178 patients with pITP were screened and 37 patients (1.7%) were observed to have developed ATE. The mean age was 62 years. Fifteen (40.5%) of the patients who developed ATEs were not receiving pITP treatment at the time of thromboembolism. Among the patients receiving pITP treatment at the time of the ATE, 9 (24.3%) were receiving eltrombopag and 10 (27%) were receiving corticosteroids. Compared to patients who did not develop ATEs, multivariate analysis revealed that the presence of hypertension, comorbidity, and history of venous thromboembolism statistically significantly increased the risk of developing ATEs (p=0.008, p=0.018, and p=0.038, respectively). Conclusion: The risk of ATEs may increase in pITP patients both during and without treatment. It is important to inquire thoroughly about the presence of comorbidities, atherosclerotic risk factors, hypertension, and history of thrombosis in these patients at the initiation of treatment. Correctable risk factors should be addressed to minimize the number of risk factors present. The treatment of pITP must be individualized, including consideration of age-related disorders.
  • [ X ]
    Öğe
    Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients
    (SPRINGER, 2025) Küçükyurt, S; Koca, O; Demirsoy, ET; Akın, S; Doğan, A; Gören, D; Yiğitbaşı, A; Şahin, O; İpek, Y; Çiftçiler, R; Şahin, F; Mengüç, MU; Özünal, İE; Kösemehmetoğlu, ÖS; Özgür, Y; Atalay, F; Öztürk, HBA; Yüksel, M; Kanat, NT; Uysal, A; İltar, U; Yıldız, A; Karadağ, FK; Baysal, M; Uğur, MC; Güven, S; Pınar, İE; Mehtap, Ö; Barista, İ; Demir, AM; Yeral, M; Selim, C; Saydam, G; Atagündüz, İK; Tiğlioğlu, P; Dilek, İ; Ayer, M; Güneş, AK; Yüksel, MK; Ünal, A; Salim, O; Soyer, N; Ateşoğlu, EB; Eskazan, AE
    Primary mediastinal B-cell lymphoma (PMBCL) is a rare and distinct subtype of non-Hodgkin lymphoma. No consensus exists on optimal frontline treatment, and the use of R-CHOP +/- radiotherapy (RT) and DA-EPOCH-R +/- RT remains common, yet comparative real-world data are limited. In our multicenter retrospective study, we analyzed PMBCL patients, stratified by the first-line therapy (R-CHOP-21 +/- RT or DA-EPOCH-R +/- RT). Primary outcomes were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS), alongside assessment of treatment-related toxicities and prognostic factors for PFS and OS. We included 157 patients [R-CHOP +/- RT group (n = 80) and DA-EPOCH-R +/- RT group (n = 77)] with a median age of 31 years, of whom 68.2% were female. CR rates were similar for R-CHOP +/- RT (75%) and DA-EPOCH-R +/- RT (76.6%). RT use was higher in the R-CHOP group (41.2% vs. 19.5%, p = 0.002). DA-EPOCH-R had significantly higher toxicity (29.9% vs. 16.2%, p = 0.033). The median follow-up of the entire cohort was 29 months with 2-year PFS and OS rates of 73.9% and 83.6%, respectively. Also, PFS and OS did not differ between regimens. In patients achieving CR with R-CHOP, RT omission did not impact survival. Multivariate analysis identified older age, poor performance status, superior vena cava syndrome and splenic involvement as independent OS predictors, while pericardial effusion, splenic involvement and hemoglobin < 10.5 g/dL were linked to inferior PFS. R-CHOP-21 +/- RT and DA-EPOCH-R +/- RT provide comparable efficacy in PMBCL. Due to the higher toxicity of DA-EPOCH-R, for those achieving CR following R-CHOP, selective RT omission may be a reasonable alternative. Established and disease-specific prognostic factors should guide individualized treatment strategies.